Page last updated: 2024-11-01

ondansetron and Cardiovascular Abnormalities

ondansetron has been researched along with Cardiovascular Abnormalities in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Cardiovascular Abnormalities: Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS.

Research Excerpts

ExcerptRelevanceReference
"The potent hERG channel blocking drug ondansetron is used off-label for treatment of nausea and vomiting in early pregnancy."3.88Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade. ( Danielsson, B; Ritchie, HE; Webster, WS, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Danielsson, B1
Webster, WS1
Ritchie, HE1

Other Studies

1 other study available for ondansetron and Cardiovascular Abnormalities

ArticleYear
Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade.
    Reproductive toxicology (Elmsford, N.Y.), 2018, Volume: 81

    Topics: Abnormalities, Drug-Induced; Animals; Antiemetics; Cardiovascular Abnormalities; Embryo, Mammalian;

2018